reviewischemic heart diseasearterial hypertentionerectile dysfunctiontreatmentPDE-5 inhibitorsобзоришемическая болезнь сердцаартериальная гипертонияэректильная дисфункциялечениеингибиторы фосфодиэстеразы 5-го типа1.Braun М., Wassner G., Klotz T. et al. Epidemiology of erectile dysfunction: results of the "Cologne Male Survey". Int. J. Impot. Res. 2000; 12 (6): 305-311.2.Wabrek A. J., Burchell С Male sexual dysfunction associated with coronary artery disease. Arch. Sex. Behav. 1980; 9: 69- 75.3.Dhabuwala С. В., Kumar A., Pierce J. M. Myocardial infarction and its influence on male sexual function. Arch. Sex. Behav. 1986; 15: 499-504.4.Diokno A. C, Brown M. В., Herzog R. Sexual function in the eldery. Arch. Intern. Med. 1990; 150: 197-200.5.Kirby M., Jackson C, Betteridge J., Friedli K. Is erectile dysfunction a marker for cardiovascular disease? Int. J. Clin. Pract. 2001; 55: 614-618.6.Kloner R. A., Mullin S. H., Shook T. et al. Erectile dysfunction in the cardiac patient: how common and should we treat? J. Urol. (Baltimore) 2003; 170: 46-50.7.Montorsi F., Briganti A., Salonia A. et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur. Urol. 2003; 44: 360-365.8.Greenstein A., Chen J., Miller H. et al. Does severity of ischemic coronary disease correlate with erectile dysfunction?Int. J. Impot. Res. 2001; 9: 123-126.9.Sullivan M. £., Keoghane S. R., Miller M. A. W. Vascular risk factors and erectile dysfunction. Br. J. Urol. 2001; 87: 838- 845.10.Feldman H. A., Goldstein I., Hatzichristou D. G. et al. // Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J. Urol. (Baltimore) 1994; 151:54-61.11.Parazzini F, Menchini F. F, Bortolotti A. et al. Frequency and determinants of erectile dysfunction in Italy. Eur. Urol. 2000; 37: 43-49.12.Toblli J. E., Stella I., Ferder L. et al. Morphological changes in cavernous tissue in spontaneously hypertensive rats. Am. J. Hypertens. 2000; 13: 686-692.13.Wassertheil-Smoller S., Blaufox M. D., Oberman A. et al. Effect of antihypertensives on sexual function and quality of life: the TAIM study. Ann. Intern. Med. 1991; 114: 613-620.14.Арабидзе Г. Г., Арабидзе Pp. Г. Антигипертензивная терапия и половая функция у мужчин. Клин, фармакол. и тер. 1999; 3: 49-52.15.Саго J. L. L., Vidal L., Vicente J. A. et al. Sexual dysfunction in hypertensive patients treated with losartan. Am. J. Med. Sci. 2001; 321: 336-340.16.Fogari R., Zoppi A., Poletti L. et al. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study.Am. J. Hypertens. 2001; 14: 27-30.17.Roumeguere Т., Wespes Е., Carpentier Y. et al. Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk. Eur. Urol. 2003; 44: 355-359.18.Solomon H., Man J. W., Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 2003; 89: 251-253.19.Rosen R. C, Weiner D. N. Cardiovascular disease and sleeprelated erections. J. Psychosom. Res. 1997; 42: 515-518.20.Rizvi K., Hampson J. P., Harvey J. N. Do lipid-lowering drugs cause erectile dysfunction? A systematic review. Fam. Pract. 2002; 19: 95.21.Shabsigh R., Fishman I. J., Schum С et al. Cigarette smoking and other vascular risk factors in vasculogenic impotence. Urology 1991; 38:227-232.22.Pittilo R. M. Cigarette smoking and endothelial injury: a review. In: Dana J. N. et al. Tobacco smoking and atherosclerosis. New York: Plenum Press; 1990: 61-78.23.Mil D. N. Implication of insulin-like growth factors in the pathogenesis of diabetic neuropathy. Brain. Res. Rev. 1995; 20: 47-67.24.Rosen M. P., Greenfield A. J., Goldstein I. Arteriogenic impotence: findings in 195 impotent men examined with selective internal pudendal angiography. Radiology 1990; 174: 1043- 1050.25.Solomon H., Man J. W., Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 2003; 89: 251-253.26.Mass R., Schwedhelem E., Albseier J., Boger R. H. The pathophysiology of erectile dysfunction related to endothelial dys- function and mediators of vascular function. Vase. Med. 2002; 7: 213-225.27.О'Kane P. D., Jackson G. Erectile dysfunction: is there silent obstructive coronary artery disease? Int. J. Clin. Pract. 2001; 55: 219-220.28.Kawanishi Y., Lee K. S., Kimura K. et al. Screening of ischem ic heart disease with cavernous artery blood flow in erectile dysfunctional patients. Int. J. Impot. Res. 2001; 13: 100-102.29.Kim S. W., Paick J. S., Park D. W. et al. Potential predictors of asymptomatic ischemic heart disease in patients with vasculogenic erectile dysfunction. Urology 2001; 58: 441-445.30.Hatzichristou D., Hatzimouratidis K, Bekas M. et al. Diagnostic steps in the evaluation of patients with erectile dysfunction. J. Urol. (Baltimore) 2002; 168: 615-620.31.Montorsi F., Briganti A., Salonia A. et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur. Urol. 2003; 44: 360-365.32.Montorsi P., Montorsi J., Schulman С. С. Is erectile dysfunction the "tip of the iceberg" of a systemic vascular disorder? Eur. Urol. 2003; 44: 352-354.33.Lue T. F. Physiology of penile erection and pathophysiology of erectile dysfunction and priapism. In: Cambell's urology. Philadelphia: Saunders; 2002. 1591-1618.34.Agarwal A., Jain D. С Male sexual dysfunction after stroke. J. Assoc. Physicians India 1989; 37: 505-508.35.May A. G., DeWeese J. A., Rob С G. Changes in sexual function following operation on the abdominal aorta. Surgery 1969; 65: 41-47.36.Parzeller M., Raschka C, Bratzke H. Sudden cardiovascular death in correlation with sexual activity: results of a medicolegal postmortem study from 1972-1998. Eur. Heart. J. 2000; 22: 610-611.37.Drory Y. Sexual activity and cardiovascular risk. Eur. Heart J. 2002; 24 (4, suppl. H): 13-18.38.Feenstra J., van Drie-Pierik R. J. H. M., Lack С F., StriekerВ. Н. С. Н. Acute myocardial infarction associated with sildenafil. Lancet 1998; 352: 957-958.39.Palmore E. B. Predictors of the longevity difference: a 25-year followup. Gerontologist 1982; 22: 513-518.40.Persson G. Five-year mortality in a 70-year-old urban population in relation to psychiatric diagnosis, personality, sexuality and yearly prenatal death. Acta Psychiatr. Scand. 1981; 64: 244-253.41.Muller J. E., Mittleman A., Maclure M. et al. Triggering myocardial infarction by sexual activity: low absolute risk and prevention by regular physical exertion. Determinants of Myocardial Infarction Onset Study Investigators. J. A. M. A. 1996- 275: 1405-1409.42.Drory Y., Fisman E. X., Shapiro Y., Pines A. Ventricular ar rhythmias during sexual activity in patients with coronary artery disease. Chest 1996; 109: 922-924.43.Lue T. F. Erectile dysfunction. N. Engl. J. Med. 2000, 324: 1801-1813.44.Rotella D. P. Phosphodiesterase 5 inhibitors: current status and potential applications. Nat. Rev. Drug Discov. 2002; 1: 674-682.45.Montorsi J., Salonia A., Deho F. et al. Pharmacological management of erectile dysfunction. Br. J. Urol. 2003; 91: 446-454.46.Мазо Е. Б., Дмитриев Д. Г., Гамидов С. И., Овчинников Р. И. Фармакотерапия эректильной дисфункции. Рус. мед. журн. 2001; 9: 1077-1078.47.Carson С. С. Sildenafil: a 4-year update in the treatment of 20 million erectile dysfunction patients. Curr. Urol. Rep. 2003; 4: 488-496.48.Corbin J. D., Francis S. H., Webb D. J. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology 2002; 60:4-11.49.Kloner R. A. Erectile dysfunction in the cardiac patient. Curr. Urol. Rep. 2003; 4: 466-471.50.Conti С R., Pepine С J., Sweeney M. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am. J. Cardiol. 1999; 338: 1397-1404.51.Kloner R. A., Brown M., Prisant L. M. et al. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil study group. Am. J. Hypertens. 2001; 14: 70-73.52.Kloner R. A., Jarow J. P. Erectile dysfunction and sildenafil ci trate and cardiologist. Am. J. Cardiol. 1999; 83: 576-582.53.Sugiyama A., Satoh Y., Shiina H. et al. Cardiac electrophysiologic and hemodynamic effects of sildenafil, a PDE5 inhibitor, in anesthetized dogs. J. Cardiovasc. Pharmacol. 2001; 38: 940-946.54.Sofowra G., Dishy V., Roden D. et al. The effect of sildenafil on QT interval in healthy men. Clin. Pharmacol. Ther. 2001; 69 (2): 67.55.Muller J. E., Mittleman A., Maclure M. et al. Triggering myocardial infarction by sexual activity: low absolute risk and prevention by regular physical exertion. Determinants of Myocardial Infarction Onset Study Investigators. J. A. M. A. 1996; 275: 1405-1409.56.Emmick J. Т., Stuewe S. R., Mitchell M. Overview of cardiovascular effects of tadalafil. Eur. Heart J. 2002; 24 (4, suppl.): 32-47.57.Carrier S., Herschorn S., Elhilali M. et al. Cardiovascular safety of Levitra (vardenafil) in patients with erectile dysfunction: an analysis of five placebo-controlled clinical trials. Can. J. Urol. 2003; 10: 1826-1829.58.Zusman R. M., Pisant L. M., Brown J. M. Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. J. Hypertens. 2000; 18: 1865-1869.59.Webb D. J, Freestone S., Allen M. J., Muirhead G. J. Sildenafil citrate and blood pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist.Am. J. Cardiol. 1999; 83: 21-28.60.Kloner R. A., Emmick J., Bedding A., Humen D. Pharmacodynamic interactions between tadalafil and nitrates. J. Am. Coll. Cardiol. 2002; 39 (suppl. A): 291.61.Cheitlin M. D., Nutter A. M., Brindis R. G. et al. ACC/AHA Expert Consensus Document. Use of sildenafil (Viagra) in patients with cardiovascular disease. J. Am. Coll. Cardiol. 1999; 33: 273-282.62.Feenstra J., van Drie-Pierik R. J. H. M., Lack С F., Strieker В. H. С. Н. Acute myocardial infarction associated with sildenafil. Lancet 1998; 352: 957-958.63.Arruda-Olson A. M., Mahoney D. W., Nehra A. et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized, crossover trial. J. A. M. A. 2002; 287: 719-725.64.Fox K. M., Thadani U., Ma P. Т., Nash S. D. Time to onset of limiting angina during treadmill exercise in men with erectile dysfunction and stable chronic angina: effect of sildenafil citrate. (Abstract). Circulation 2001; 107: 601-601.65.Stanopoulos I., Hatzichristou D., Try/on S. et al. Effectrs of sildenafil on cardiopulmonary responses during stress. J. Urol. (Baltimore) 2003; 169: 1417-1421.66.Thadani U., Smith W., Nash S. et al. Effect of vardenafil on the cardiovascular responses to exercise in men with coronary artery disease. J. Am. Coll. Cardiol. 2002; 40: 2006-2012.67.Thadani U., Chrysant S., Mazzu A. The effect of vardenafil, a selective PDE-5 inhibitor, on ischemic threshold, exercise tolerance, and circulatory responses during treadmill exercise in men with stable angina pectoris. J. Am. Coll. Cardiol. 2003; 41: 336-339.68.Padma-Nathan H., Eardley I., Kloner R. A. et al. A 4-year update on the safety of sildenafil citrate (Viagra). Urology 2002: 60 (suppl. 2B): 67-90.69.Wysomki D. К., Farinas Е., Swartz L. Comparison of re] and expected deaths in sildenafil (Viarga) users. Am. J. < ol. 2002; 89: 13311334.70.DeBusk R., Drory Y., Goldstein I. et al. Management of dysfunction in patients with cardiovascular disease: recon dations of the Princeton Consensus Panel. Am. J. Ca 2000; 86: 62-68.